Liver Cancer Arterial Therapies

Liver Cancer Transarterial Therapies: TACE, DEB-TACE, and Y-90 Radioembolization (TARE) for Targeted Tumor Treatment

Oncology Interventional Procedures | Interventional Cancer Procedures
Cancer Treatment | Age: Adults | Geriatrics

What is Liver Cancer Transarterial Therapies: TACE, DEB-TACE, and Y-90 Radioembolization (TARE) for Targeted Tumor Treatment?

Liver cancer transarterial therapies are minimally invasive interventional oncology treatments designed to target liver tumors directly through their blood supply. Techniques such as Transarterial Chemoembolization (TACE), Drug-Eluting Bead TACE (DEB-TACE), and Y-90 Radioembolization (TARE) deliver chemotherapy or radiation precisely to the tumor while limiting exposure to healthy liver tissue. Using image guidance, these therapies slow tumor growth, reduce symptoms, and can downstage disease for additional treatment options.

Commonly used for primary liver cancer and selected metastatic disease, these catheter-based treatments are alternatives or complements to surgery and systemic therapy. They are performed with a focus on tumor control, quality of life, and preservation of liver function.

Conditions Treated

  • Hepatocellular carcinoma (HCC)
  • Liver-dominant metastatic cancer
  • Inoperable or unresectable liver tumors
  • Tumors awaiting transplant or surgery (bridging therapy)
  • Recurrent liver cancer

Internal links: Oncology Interventional Procedures, Interventional Cancer Procedures, Cancer Treatment

Benefits of Liver Cancer Transarterial Therapies vs Surgery

Transarterial Therapies (TACE / DEB-TACE / TARE)

  • Minimally invasive, no major incision
  • Outpatient or short hospital stay
  • Faster recovery
  • Lower complication risk
  • Targeted tumor treatment

Liver Surgery

  • Open or laparoscopic surgery
  • Longer hospitalization
  • 2 Extended recovery time
  • Higher surgical risks
  • Less selective tissue impact

How the Procedure Works

  • A catheter is inserted through an artery in the groin or wrist.
  • Imaging maps the arteries feeding the liver tumor.
  • Chemotherapy beads (TACE/DEB-TACE) or Y-90 microspheres (TARE) are delivered.
  • Tumor blood supply is blocked or irradiated.
  • Imaging confirms accurate treatment delivery.
  •  

What to Expect (Before, During & After)

Risks & Considerations

Liver cancer transarterial therapies are well established and generally safe when performed by experienced interventional oncologists. Possible risks include post-embolization syndrome (pain, fever, fatigue), infection, or temporary changes in liver function. Careful patient selection and imaging guidance help minimize complications and maximize treatment

Frequently asked question

TACE uses chemotherapy mixed with embolic material, DEB-TACE uses drug-eluting beads for controlled drug release, and Y-90 delivers targeted internal radiation. The choice depends on tumor type, size, and liver function.

Yes, Y-90 is a form of internal radiation delivered directly to liver tumors. It limits radiation exposure to surrounding healthy tissue.

They are primarily used to control tumor growth and prolong survival. In some cases, they can downstage tumors for surgery or transplant.

This varies by tumor response and overall health. Some patients require a single session, while others benefit from staged or repeat treatments.

Take control of your health with minimally invasive liver cancer transarterial therapies.